Inhibrx Biosciences Stock Price | INBX Stock Quote, News, and History
| Date | Open | Close | Daily High | Daily Low |
|---|
Price change over selected period: 0% 0
Total Analysts: 0
Buy Ratings: 0 Neutral Ratings: 0 Sell Ratings: 0
Analyst: {{ANALYST_DATA}}
Price-Target: {{PRICE_DATA}}
Rating: {{RATING_DATA}}
Price *Price Target
Lowest: 0.00 Median: 0.00 Highest: 0.00
- All
- Buy
- Hold
- Sell
- Yearly
- Quarterly
| 2024 | 2025 | 2026 | 2027 | 2028 | |
|---|---|---|---|---|---|
| Revenue | 1 | 1 | 1 | 117 | 209 |
| Dividend | - | - | - | - | - |
| Dividend Yield (in %) | - | - | - | - | - |
| EPS | -11.73 | -9.56 | -8.07 | -4.06 | -1.14 |
| P/E Ratio | -1.21 | -1.49 | -1.76 | -3.50 | -12.48 |
| EBIT | -213 | -211 | -148 | -69 | -6 |
| EBITDA | - | - | - | - | - |
| Net Profit | -210 | -207 | -157 | -84 | -25 |
| Net Profit Adjusted | -241 | -226 | - | - | - |
| Pre-Tax Profit | -210 | -207 | -157 | -84 | -25 |
| Net Profit (Adjusted) | - | - | - | - | - |
| EPS (Non-GAAP) ex. SOE | - | - | - | - | - |
| EPS (GAAP) | - | - | - | - | - |
| Gross Income | 1 | 1 | 1 | 94 | 178 |
| Cash Flow from Investing | 235 | 150 | 125 | 125 | 50 |
| Cash Flow from Operations | -160 | -166 | -154 | -112 | -51 |
| Cash Flow from Financing | 235 | 150 | 125 | 125 | 50 |
| Cash Flow per Share | - | - | - | - | - |
| Free Cash Flow | - | - | - | - | - |
| Free Cash Flow per Share | - | - | - | - | - |
| Book Value per Share | - | - | - | - | - |
| Net Debt | 0 | 0 | 0 | 0 | - |
| Research & Development Exp. | 180 | 176 | 109 | 115 | 121 |
| Capital Expenditure | 2 | 2 | 2 | 2 | 2 |
| Selling, General & Admin. Exp. | 39 | 40 | - | - | - |
| Shareholder’s Equity | 69 | -98 | -232 | -293 | -294 |
| Total Assets | 102 | 86 | 77 | 141 | 192 |
| Previous Quarter ending 06/30/24 | Current Quarter ending 09/30/24 | Next Quarter ending 12/31/24 | Current Year ending 12/31/24 | Next Year ending 12/31/25 | |
|---|---|---|---|---|---|
| Earnings Estimates | |||||
| No. of Analysts | 1 | 1 | 1 | 2 | 2 |
| Average Estimate | -3.600 USD | -3.750 USD | -3.810 USD | -11.730 USD | -9.555 USD |
| Year Ago | - | - | - | -5.121 USD | - |
| Publish Date | - | - | - | - | - |
| Revenue Estimates | |||||
| No. of Analysts | 1 | 1 | 1 | 2 | 2 |
| Average Estimate | 0 USD | 0 USD | 0 USD | 1 USD | 1 USD |
| Year Ago | - | - | - | 2 USD | - |
| Publish Date | - | - | - | - | - |
* Average Estimates in Million (e.g. Revenue) or per share (e.g. Dividend). Source: FactSet
| Date | Name | Dividend | *yield | Currency |
|---|---|---|---|---|
| 2023 | Inhibrx Biosciences Inc Registered Shs When Issued | - | - | USD |
| 2022 | Inhibrx Biosciences Inc Registered Shs When Issued | - | - | USD |
*Yield of the Respective Date
Inhibrx Biosciences, Inc. operates as an American clinical-stage biotechnology company for biologic therapeutic candidates. The private company is based in DE.
| Owner | in % |
|---|---|
| Freefloat | 69.91 |
| Viking Global Investors LP | 12.35 |
| Perceptive Advisors LLC | 10.10 |
| RA Capital Management LP | 8.17 |
| Sanofi | 8.00 |
| Jon Faiz Kayyem, PhD | 7.56 |
| Mark Paul Lappe | 5.26 |
| BlackRock, Inc. | 4.69 |
| Brendan P. Eckelman, PhD | 3.55 |
| Vanguard Total Stock Market ETF | 2.10 |
| Douglas Gorman Forsyth, CFA | 1.03 |
| Vanguard Extended Market Index Fund | 0.69 |
Shareholder percentage totals can add to more than 100% because some holders are included in the free float.
ncG1vNJzZmilkae4psDSZ5muq5mjsrS%2FyKeqopyVp3uku8xoqq2nk6DAcLXNm69mq6SksKw%3D